1. Home
  2. IBG vs VTAK Comparison

IBG vs VTAK Comparison

Compare IBG & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IBG

Innovation Beverage Group Limited Ordinary Shares

HOLD

Current Price

$3.79

Market Cap

2.5M

ML Signal

HOLD

Logo Catheter Precision Inc.

VTAK

Catheter Precision Inc.

HOLD

Current Price

$1.48

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IBG
VTAK
Founded
2018
2002
Country
Australia
United States
Employees
9
N/A
Industry
Beverages (Production/Distribution)
Medical/Dental Instruments
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5M
2.9M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
IBG
VTAK
Price
$3.79
$1.48
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
130.7K
65.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
89.53
EPS
N/A
N/A
Revenue
N/A
$442,000.00
Revenue This Year
N/A
$822.86
Revenue Next Year
N/A
$168.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
3057.14
52 Week Low
$0.30
$0.15
52 Week High
$6.50
$4.31

Technical Indicators

Market Signals
Indicator
IBG
VTAK
Relative Strength Index (RSI) 53.57 40.91
Support Level $3.61 $1.52
Resistance Level $5.12 $2.05
Average True Range (ATR) 0.59 0.19
MACD -0.13 0.00
Stochastic Oscillator 12.15 47.67

Price Performance

Historical Comparison
IBG
VTAK

About IBG Innovation Beverage Group Limited Ordinary Shares

Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.

About VTAK Catheter Precision Inc.

Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.

Share on Social Networks: